Loading…
Sexual Assault Victims Protection Act of 2019
Legislative Progress
Introduced
October 18, 2019
Latest Action
November 15, 2019
Primary Sponsor
H. Morgan GriffithRepublican(VA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
78pct
28d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Sexual Assault Victims Protection Act of 2019 This bill requires the Department of Health and Human Services (HHS) to conduct a series of activities relating to sexual assault evidence and treatment. Among other things, HHS must establish a task force to improve forensic evidence collection related to sexual assault, maintain a website with resources and best practices related to the treatment of individuals for sexual assault, and host an annual meeting to address gaps in health care relating to sexual assault. In addition, the Centers for Medicare & Medicaid Services must require Medicare-participating hospitals, in their community call plans relating to on-call coverage, to specifically delineate coverage responsibilities with respect to screening and treatment related to sexual assault.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2024 · fourth_quarter · Health Issues
Issues related to health coverage and patient access to care. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act (Public Law 116-260) and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, The NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages. Issues related to pediatric drug development.
Client expense: Not reported · Firm income: $60,000
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
Issues related to health coverage and patient access to care. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act (Public Law 116-260) and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, The NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages. Issues related to pediatric drug development.
Client expense: Not reported · Firm income: $60,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Issues related to health coverage and patient access to care. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act (Public Law 116-260) and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, The NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages. Issues related to pediatric drug development.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Issues related to health coverage and patient access to care. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act (Public Law 116-260)and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, the NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| MN |
| Robert J. Wittman | Republican | VA |
| Steve Chabot | Republican | OH |